1. Academic Validation
  2. NMR studies of novel inhibitors bound to farnesyl-protein transferase

NMR studies of novel inhibitors bound to farnesyl-protein transferase

  • Protein Sci. 1995 Apr;4(4):681-8. doi: 10.1002/pro.5560040408.
K S Koblan 1 J C Culberson S J Desolms E A Giuliani S D Mosser C A Omer S M Pitzenberger M J Bogusky
Affiliations

Affiliation

  • 1 Department of Cancer Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
Abstract

Farnesyl-protein transferase (FPTase) catalyzes the posttranslational farnesylation of the cysteine residue located in the carboxyl-terminal tetrapeptide of the Ras oncoprotein. Prenylation of this residue is essential for the membrane association and cell-transforming activities of Ras. Inhibitors of FPTase have been demonstrated to inhibit ras-dependent cell transformation and thus represent a potential therapeutic strategy for the treatment of human cancers. The FPTase-bound conformation of a tetrapeptide inhibitor, CVWM, and a novel pseudopeptide inhibitor, L-739,787, have been determined by NMR spectroscopy. Distance constraints were derived from two-dimensional transferred nuclear Overhauser effect experiments. Ligand competition experiments identified the NOEs that originate from the active-site conformation. Structures were calculated with the combination of distance geometry and restrained energy minimization. Both peptide backbones are shown to adopt nonideal reverse-turn conformations most closely approximating a type III beta-turn. These results provide a basis for understanding the spatial arrangements necessary for inhibitor binding and selectivity and may aid in the design of therapeutic agents.

Figures
Products